

INHIBITION OF ENZYMATIC ACTIVITY OF PHOSPHOLIPASE A₂ BY MINOCYCLINE AND DOXYCYCLINE

WALDEMAR PRUZANSKI,*† ROBERT A. GREENWALD,‡ IAN P. STREET,§
FRANCE LALIBERTE,§ EVA STEFANSKI* and PETER VADAS*

*Inflammation Research Group, The Wellesley Hospital, University of Toronto, Toronto, Ontario,
Canada; ‡Long Island Jewish Medical Center, New Hyde Park, NY, U.S.A.; and

§Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, P.Q., Canada

(Received 24 February 1992; accepted 27 May 1992)

Abstract—Extracellular phospholipases A₂ play an important role in articular and extra-articular inflammatory processes. Secretory non-pancreatic phospholipase A₂ (PLA₂) has been implicated in the pathogenesis of articular inflammation in rheumatoid arthritis, whereas pancreatic PLA₂ contributes to the tissue damage associated with acute pancreatitis. Since in experimental models lipophilic tetracyclines such as minocycline and doxycycline are antiinflammatory, we examined their effects on PLA₂ activity using two assay systems *in vitro*. We found that minocycline and to a lesser degree doxycycline were markedly inhibitory to both pancreatic and non-pancreatic PLA₂. Using [¹⁴C]oleic acid labeled *Escherichia coli* membrane phospholipids as substrate, the IC₅₀ values for minocycline and doxycycline were 3.6×10^{-5} M (18 µg/mL) and 0.98×10^{-4} M (47 µg/mL), respectively. In a scooting mode assay using the synthetic phospholipid 1-palmitoyl-2-(10-pyrenedecanoyl)-3-L-phosphatidylmethanol as substrate, IC₅₀ values for minocycline were 5 µM (2.47 µg/mL) for non-pancreatic PLA₂ and 8 µM (3.95 µg/mL) for pancreatic PLA₂. Addition of excess calcium up to 50 mM did not reverse the inhibitory activity of tetracyclines. We conclude that lipophilic tetracyclines inhibit PLA₂, probably by interaction with the substrate, and may be a useful adjunct in the therapy of inflammatory conditions in which PLA₂ is implicated pathogenetically.

Several semi-synthetic tetracycline antibiotics, such as minocycline and doxycycline, have been found to be powerful inhibitors of the neutral matrix metalloproteinases collagenase and gelatinase [1–9]. Inhibitory activity has been demonstrated both *in vitro* and *in vivo* in tissues as diverse as inflamed gingiva, rheumatoid synovium, cornea, osteoarthritic cartilage, and cancer cells (see Ref. 10 for review). Minocycline has also been found to inhibit the synthesis of prostaglandin E₂ (PGE₂) and 6-keto PGF_{1α} by gingival fibroblasts [11]. It has also been reported that minocycline suppresses some clinical manifestations of adjuvant and/or collagen-induced arthritis [12–14]. However, extensive studies with minocycline and doxycycline in rats with adjuvant arthritis have failed to confirm a significant effect on joint score and paw swelling while at the same time demonstrating clearly the ability of these compounds (after *in vivo* administration) to inhibit collagenase and gelatinase [15].

Several years ago a new enzyme, low molecular weight, secretory phospholipase A₂ (PLA₂), was discovered [16, 17]. This PLA₂ was found to belong to the non-pancreatic group II phospholipases [18] on the basis of its novel amino acid sequence [19]. Originally, this PLA₂ was detected in rheumatoid

synovial fluid (SF) [16, 17]. Serum PLA₂ activity correlates with disease activity in adult rheumatoid [20] and juvenile chronic [21] arthritis. Intra-articular injections of a native purified PLA₂ [22] or of recombinant human rh-PLA₂ [23] induce experimental synovitis closely resembling the proliferative rheumatoid process.

Since PLA₂ is proinflammatory, and present in the synovial milieu, it was of interest to investigate whether tetracycline derivatives modulate the activity of this enzyme. Our studies have shown that minocycline and, to a lesser degree, doxycycline substantially inhibit the PLA₂-substrate interaction.

METHODS

Minocycline and doxycycline were obtained from the Sigma Chemical Co., St. Louis, MO. Recombinant human group II PLA₂ (rh-PLA₂), Lot No. 2789, was a gift of Dr. J. Browning, Biogen, Cambridge, MA. Human group II extracellular PLA₂ (SF-PLA₂) was purified from rheumatoid synovial fluid as described [24]. Cell-free human synovial fluids were obtained from rheumatoid, osteoarthritic, and psoriatic inflamed joints. *Naja naja* PLA₂ was purchased from Sigma, and repurified as described [25]. *Crotalus adamanteus* PLA₂ (*Crot. adamanteus*), *Crotalus atrox* PLA₂ (*Crot. atrox*) and porcine pancreatic PLA₂ also were obtained from Sigma. Purified human pancreatic PLA₂ was a gift of Dr. B. Sternby, University of Lund, Sweden. Homogenates of deep and superficial human

† Corresponding author: Dr. W. Pruzanski, The Wellesley Hospital, Room 104, Jones Building, Toronto, Ontario, M4Y 1J3, Canada. Tel. (416) 926-7785; FAX (416) 966-5046.

‡ Abbreviations: PLA₂, phospholipase A₂; SF, synovial fluid; rh, recombinant human; and TET, tetracyclines.




Fig. 1. Inhibition of PLA₂ purified from rheumatoid synovial fluid (SF-PLA₂) by minocycline and doxycycline. The tetracyclines were preincubated for 30 min with PLA₂. Values are means \pm SD of triplicate experiments. Control value: 134 ± 7 U/mL.




Fig. 2. Inhibition of SF-PLA₂ and of recombinant human (rh) PLA₂ by minocycline. Values are means \pm SD of triplicate experiments. Respective control values were 137 ± 18 and 97 ± 2 U/mL.

osteoarthritic cartilage were prepared as described [26].

PLA₂ enzymatic activity. PLA₂ activity was assayed using [¹⁴C]oleic acid-labeled *Escherichia coli* membrane phospholipid as substrate [24]. Reaction mixtures contained 10 mg bovine serum albumin, 2 mM CaCl₂, 8×10^8 radiolabeled *E. coli* and 0.1 M Tris-HCl buffer, pH 7.5, in a volume of 1.5 mL. Reaction mixtures were incubated at 37° for 30 min and the reaction was terminated by filtration through a 0.45 µm Millipore filter. Assays were performed in duplicate in substrate excess. Enzyme activities were corrected for non-enzymatic hydrolysis [24].

PLA₂ scooting mode assay. A scooting mode assay [27, 28] has been developed for the PLA₂ from synovial fluid. The activities of the rh SF-PLA₂ and purified PLA₂ from porcine pancreas were measured using the synthetic phospholipid 1-palmitoyl-2-(10-pyrenedecanoyl)-3-L-phosphatidylmethanol (10-Py-PM). Vesicles containing different mole fractions of minocycline were prepared by mixing chloroform solutions of the phospholipid and the inhibitor, followed by removal of the solvent under a stream of nitrogen. The phospholipid-inhibitor mixtures were then resuspended in 1 mM ethyleneglycolbis(aminoethylether)tetra-acetate (EGTA) (pH 9.0) and sonicated in a bath sonicator. Reactions contained 10 µM 10-Py-PM, 2.5 mM CaCl₂, 100 mM KCl, and 50 mM Tris-HCl (pH 9.0). Reactions were incubated at 37° for 4 min and quenched, and the products were analyzed by HPLC (Street *et al.*, unpublished observations).

RESULTS

Using *E. coli* membrane phospholipids, minocycline in concentrations of 1×10^{-5} M to 1×10^{-4} M (5–50 µg/mL) was found to inhibit substrate hydrolysis by SF-PLA₂ in a concentration-dependent manner. The IC₅₀ was 3.6×10^{-5} M (18 µg/mL). Doxycycline tested in concentrations from 0.1×10^{-4} M to 2.0×10^{-4} M (5–100 µg/mL) was also inhibitory with an IC₅₀ of 0.98×10^{-4} M (47 µg/mL) (Fig. 1). Comparison of SF-PLA₂ and

Table 1. Inhibitors of group I and group II phospholipases A₂

Inhibitor	IC ₅₀ (µM)	
	rh SF-PLA ₂ *	Pancreatic PLA ₂ †
Gelb inhibitor	65	2
Dennis inhibitor (PE)‡	0.048	0.005
Dennis inhibitor (PC)§	0.69	0.14
Minocycline	5	8

* Recombinant human (synovial type) PLA₂.

† Purified PLA₂ from porcine pancreas.

‡ PE = ethanolamine head group.

§ PC = choline head group.

recombinant human PLA₂ showed that minocycline was more inhibitory to rh-PLA₂ (Fig. 2).

Minocycline also inhibited the rh-PLA₂ and the porcine pancreatic PLA₂ when 10-Py-PM was used as the substrate in the assay. The IC₅₀ values obtained for the rh-PLA₂ and the porcine pancreatic PLA₂ were 5 µM (2.47 µg/mL) and 8 µM (3.95 µg/mL), respectively. For comparison a number of substrate analogue-inhibitors were also tested for their ability to inhibit PLA₂ in the 10-Py-PM assay (Table 1). The phosphonate substrate analogue, described by Jain *et al.* [29] and called Gelb inhibitor, and the amidophospholipids, described by Yu *et al.* [30] and called Dennis inhibitors, were found to be effective inhibitors of both the rh-PLA₂ and the porcine pancreatic PLA₂. The impact of calcium concentration on the inhibitory activity of minocycline and doxycycline was tested at concentrations from 7 to 50 mM. Addition of excess calcium did not reverse the inhibitory activity of the tetracyclines (data not shown).

Preincubation of 40 µM minocycline (20 µg/mL) and 104 µM doxycycline (50 µg/mL) with group I

Table 2. Inhibition of group I and group II phospholipase A₂ activity by minocycline and doxycycline

Phospholipase A ₂	Minocycline, 40 μ M (20 μ g/mL)	Doxycycline, 104 μ M (50 μ g/mL)
Activity (U/mL)		
Control	91 \pm 2*	134 \pm 1
rh-PLA ₂ †	14 \pm 1 (85)‡	30 \pm 3 (78)
Control	137 \pm 18	68 \pm 8
SF-PLA ₂ §	47 \pm 4 (66)	36 \pm 3 (53)
Control	106 \pm 2	106 \pm 2
Human pancreatic	5 \pm 3 (95)	95 \pm 9 (10)
Control	223 \pm 4	223 \pm 4
Porcine pancreatic	100 \pm 3 (55)	194 \pm 13 (13)

* Mean \pm SD of 3 experiments in duplicate.† Recombinant human (synovial type) PLA₂.

‡ Values in parentheses indicate mean percent of inhibition.

§ Native purified synovial fluid PLA₂.

and group II phospholipases A₂ (Table 2) showed that minocycline was consistently more inhibitory than doxycycline. Minocycline inhibited PLA₂ in rheumatoid, osteoarthritic and psoriatic synovial fluids (62–68% inhibition) and in the homogenate of superficial and deep human osteoarthritic articular cartilage (62–71% inhibition). The respective inhibition by doxycycline was 26–57 and 33–38%. *Naja naja* (group I) PLA₂ activity was strongly inhibited by minocycline (72%) but not by doxycycline (12%). Phospholipases A₂ from the venoms of *Crot. atrox* and *Crot. adamanteus* (Group II enzymes) were inhibited by minocycline (22 and 43%, respectively) but not by doxycycline. Preincubation of minocycline (40 μ M, 20 μ g/mL) and doxycycline (104 μ M, 50 μ g/mL) for 30 min with the substrate showed inhibition essentially identical to that obtained when the tetracyclines were preincubated with the enzymes (data not shown).

DISCUSSION

Minocycline and doxycycline are highly lipid soluble tetracyclines (TET) that easily penetrate body tissues and fluids including synovial fluid [31]. Both these TET, as well as others which have been modified so as to remove their antibiotic activity, were found to exert marked inhibitory activity on matrix metalloproteinases, such as collagenases, gelatinase and macrophage elastase (see Ref. 10 for review).

Synovial fluids and tissues from patients with rheumatoid arthritis treated with minocycline have markedly lower collagenase activity as compared to pretreatment values [5]. Doxycycline inhibits digestion of exogenous type XI collagen by homogenates of human articular cartilage [8].

These studies [1–10] prompted trials to attenuate experimental arthritis by TET. It was suggested that minocycline suppressed collagen II and adjuvant arthritis in the rat [12–14]. However, in another

study, oral TET given as a single agent to rats had no substantial antiinflammatory activity as assessed by joint swelling and paw diameter but it inhibited collagenase activity. A combination of the non-steroidal agent flurbiprofen and TET potently inhibits inflammation and normalized radiographic joint damage [15]. Thus, simultaneous administration of cyclooxygenase inhibitors and lipid-soluble TET seems to have a more pronounced beneficial effect in experimental arthritis than when each agent is given separately.

In several small series of patients with rheumatoid or reactive arthritis, minocycline and doxycycline were shown to have some beneficial effect on arthritis [32–34]. Tetracycline hydrochloride given to patients with rheumatoid arthritis showed no significant benefit [35]. However, these were all open trials and were statistically inconclusive.

The impact of tetracyclines on the arachidonic acid cascade has not been studied extensively. Preliminary study has shown that tetracycline and minocycline inhibit the activity of partially purified PLA₂ from venom of *Crot. adamanteus* [36]. It was also reported that minocycline added to the cultures of gingival fibroblasts inhibits the synthesis of PGE₂ and 6-keto PGF_{1 α} [11].

The above observation combined with the fact that TET are inhibitory to several metalloproteinases prompted us to investigate the impact of TET on a panel of structurally distinct phospholipases A₂. Since in several models, low molecular weight extracellular PLA₂ was found to have proinflammatory activity [22, 23, 37, 38], inhibition of this enzyme by TET would serve as an additional rationale to use TET in arthritis alone or in combination with antiinflammatory agents. Our study has shown that minocycline and doxycycline markedly inhibit proinflammatory synovial-type phospholipase A₂ in both *E. coli* assay and in the scooting mode assay. Minocycline was a more potent inhibitor than doxycycline. Both TET showed

selectivity towards certain PLA₂s. Minocycline was markedly inhibitory to both group I and II PLA₂ of human origin. In the snake venom PLA₂s minocycline was slightly more inhibitory to group I PLA₂ (*Naja naja*) than to group II (*Crot. atrox* and *Crot. adamanteus*). Doxycycline substantially inhibited human group II PLA₂s, but had no inhibitory activity against pancreatic PLA₂ and snake venom PLA₂s. It is not clear why minocycline was found to be more inhibitory than doxycycline whereas the opposite is true in the studies of collagenase inhibition [5, 10]. Perhaps some differences in lipophilic properties may account for the above phenomenon. An increase of calcium concentration in the reaction mixtures did not reverse the inhibitory activity of TET, thereby suggesting that chelation of calcium by TET is not the mechanism of PLA₂ inhibition.

Many group I PLA₂s have a high affinity for vesicles containing anionic phospholipids, and hydrolyse these substrates without leaving the lipid-water interface [27]. Under these conditions (scooting mode hydrolysis), it is possible to differentiate between inhibitors which bind at the catalytic site of the enzyme and those compounds which exert their inhibitory effect by decreasing the affinity of the enzyme for the lipid-water interface [28].

Kinetic studies with PLA₂ are complicated by the fact that binding of the enzyme to the lipid-water interface must precede catalytic turnover. Compounds which affect the organization of the substrate interface, and consequently the amount of absorbed enzyme, can alter apparent turnover rates by up to several orders of magnitude. By monitoring the kinetics of interfacial catalysis in the scooting mode [29] it is possible to differentiate between compounds which inhibit PLA₂ by desorption of the enzyme from the substrate interface (nonspecific inhibitors) and compounds which inhibit PLA₂ directly by binding at the active site. In the scooting mode the PLA₂ has a very high affinity for the substrate interface and remains tightly bound to the substrate vesicle during and after hydrolysis of all of the available substrate [39]. The effect of nonspecific inhibitors is minimized and it is possible to detect desorption of the enzyme from the interface. Examples of compounds which inhibit the action of PLA₂ by affecting interface structure include lipocortin [40], alkanols [41], cationic amphiphiles [42] and aristolochic acid [43]. None of these compounds has any effect on PLA₂ activity in the scooting mode [29].

The group II rh SF-PLA₂ has a high affinity for the anionic interface of 10-Py-PM vesicles and remains tightly bound to the vesicle surface for many catalytic cycles (Street *et al.*, unpublished observations). Therefore, it was of interest to examine minocycline and a number of known substrate analogue inhibitors of PLA₂ in the 10-Py-PM assay system. The results presented in Table 1 show that the phosphonate inhibitor (Gelb inhibitor) and particularly the amidophospholipids described by Yu *et al.* [30] were potent inhibitors of both the rh SF-PLA₂ and the porcine pancreatic PLA₂. In the case of the amidophospholipid analogue possessing the ethanolamine head group (Dennis-PE), 50% inhibition of the rh SF-PLA₂ was observed

in vesicles containing only a 0.048 μ M concentration of the inhibitor.

Minocycline codispersed with 10-Py-PM was inhibitory to both the rh SF-PLA₂ and the porcine pancreatic PLA₂. However, inhibition of these enzymes was observed only when minocycline was present in the assay at concentrations approaching that of the substrate. Minocycline is one of the most lipophilic tetracyclines and will partition essentially completely into the lipid phase. Thus, at the concentration of minocycline required for 50% inhibition of the rh SF-PLA₂ (5 μ M) the inhibitor constituted 30 mol% of the substrate vesicle. At this very high interfacial concentration, minocycline may cause structural changes to the substrate vesicle and it is likely that most of the inhibition is due to these effects and dilution of the substrate within the vesicle. However, as this study only involved the measurement of initial rates, the possibility that minocycline does bind at the active site cannot be excluded completely.

Irrespective of the mechanism of the inhibitory activity of TET, they may potentially be useful as adjuncts in the treatment of inflammatory arthritides. TET may also be used in acute pancreatitis. Pancreatic PLA₂ converts lecithin to lysolecithin which may cause marked inflammatory reaction [44]. In acute pancreatitis the release of large amounts of pancreatic PLA₂ into the pancreatic and adjacent tissues has been well documented [45]. Furthermore, the circulating levels of PLA₂ in the serum of patients with pancreatitis may increase up to 800-fold from the normal level [46]. Since TET markedly inhibit pancreatic PLA₂-substrate interaction, their use in conditions in which this enzyme is excessively activated and released from the pancreas may be clinically beneficial.

Acknowledgements—This work was supported by grants-in-aid from the Medical Research Council of Canada and The Arthritis Society.

REFERENCES

1. Golub LM, Lee HM, Lehrer G, Ramamurthy N and McNamara TF, Minocycline reduces gingival collagenolytic activity during diabetes: Preliminary observations and a proposed new mechanism of action. *J Periodont Res* 18: 516–524, 1983.
2. Golub LM, Wolff M, Lee HM, McNamara TF, Ramamurthy NS, Zambon J and Ciancio S, Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. *J Periodont Res* 20: 12–23, 1985.
3. Gomes BC, Golub LM and Ramamurthy NS, Tetracyclines inhibit parathyroid hormone induced bone resorption in organ culture. *Experientia* 40: 1273–1275, 1985.
4. Rifkin RB, Golub LM, Sanavi R, Vernillo AT, Kleckner AP, McNamara TF, Auszmann JM and Ramamurthy NS, Effects of tetracyclines on rat osteoblast collagenase activity and bone resorption *in vitro*. In: *The Biological Mechanisms of Tooth Movement and Craniofacial Adaptation* (Ed. Davidovitch Z), pp. 85–90. EBSCO Media, Birmingham AL, 1992.
5. Greenwald RA, Golub LM, Laviates B, Ramamurthy NS, Gruber B, Laskin RS and McNamara TF,

- Tetracyclines inhibit human synovial collagenase *in vivo* and *in vitro*. *J Rheumatol* **14**: 28–32, 1987.
6. Golub LM, McNamara TF, D'Angelo G, Greenwald RA and Ramamurthy NS, A nonantibacterial chemically modified tetracycline inhibits mammalian collagenase activity. *J Dent Res* **66**: 1310–1314, 1987.
 7. Burns FR, Stack MS, Gray RD and Paterson CA, Inhibition of purified collagenase from alkali-burned rabbit corneas. *Invest Ophthalmol Vis Sci* **30**: 1569–1575, 1989.
 8. Yu LP Jr, Smith GN, Hasty KA and Brandt KD, Doxycycline inhibits Type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. *J Rheumatol* **18**: 1450–1452, 1991.
 9. Zucker S, Lysik RM, Ramamurthy NS, Golub LM, Wieman JM and Wilkie DP, Diversity of melanoma membrane proteinases: Inhibition of collagenolytic and cytolytic activity by minocycline. *J Natl Cancer Inst* **75**: 517–525, 1985.
 10. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA and Rifkin BR, Tetracyclines inhibit connective tissue breakdown: New therapeutic implications for an old family of drugs. *Crit Rev Oral Med Pathol* **2**: 297–322, 1991.
 11. ElAttar TMA, Lin HS and Schulz R, Effect of minocycline on prostaglandin formation in gingival fibroblasts. *J Periodont Res* **23**: 285–286, 1988.
 12. Breedveld FC, O'Brien JM, Brinckerhoff CE and Trentham DE, Suppression of collagen and adjuvant arthritis by a tetracycline. *Arthritis Rheum* **31** (Suppl): S88, 1988.
 13. Sewell KL, Fury E, Dynesius-Trentham R, Tomyk K and Trentham DE, Evidence that minocycline suppresses collagen and adjuvant arthritis by altering the expression of T cell derived, collagen-binding proteins. *Arthritis Rheum* **32** (Suppl): S134, 1989.
 14. Sewell KL, Furrie SE and Trentham DE, The therapeutic effect of minocycline in experimental arthritis. Mechanism of action. *Arthritis Rheum* **33** (Suppl): S106, 1991.
 15. Greenwald RA, Moak SA, Ramamurthy NS and Golub LM, Tetracyclines suppress metalloproteinase activity in adjuvant arthritis and, in combination with flurbiprofen, ameliorate bone damage. *J Rheumatol* **19**: 927–938, 1992.
 16. Vadas P and Pruzanski W, The role of extracellular phospholipase A₂ in inflammation. *Adv Inflammation Res* **7**: 51–62, 1983.
 17. Vadas P and Pruzanski W, Role of secretory phospholipase A₂ in the pathology of disease. *Lab Invest* **55**: 391–399, 1986.
 18. Heinrikson RL, Kreuger ET and Keim PS, Amino acid sequence of phospholipase A₂-α from the venom of *Crotalus adamanteus*. A new classification of phospholipases A₂ based upon structural determinants. *J Biol Chem* **252**: 4913–4921, 1977.
 19. Seilhamer JJ, Pruzanski W, Vadas P, Plant S, Miller JA, Kloss J and Johnson LK, Cloning and recombinant expression of phospholipase A₂ present in rheumatoid arthritic synovial fluid. *J Biol Chem* **264**: 5335–5338, 1989.
 20. Pruzanski W, Vadas P, Stefanski E and Urowitz M, Phospholipase A₂ activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis. *J Rheumatol* **12**: 211–216, 1986.
 21. Silverman E, Pruzanski W, Laxer R, Albin-Cook K, Stepanovic E and Vadas P, Correlation of phospholipase A₂ level and disease activity in juvenile rheumatoid arthritis (JRA). *Arthritis Rheum* **30** (Suppl): S127, 1987.
 22. Vadas P, Pruzanski W, Kim J and Fornasier V, The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A₂. *Am J Pathol* **134**: 807–811, 1989.
 23. Bomalaski JS, Lawton P and Browning JL, Human extracellular recombinant phospholipase A₂ induces an inflammatory response in rabbit joints. *J Immunol* **146**: 3904–3910, 1991.
 24. Stefanski E, Pruzanski W, Sternby B and Vadas P, Purification of a soluble phospholipase A₂ from synovial fluid in rheumatoid arthritis. *J Biochem (Tokyo)* **100**: 1297–1303, 1986.
 25. Deems RA and Dennis EA, Phospholipase A₂ from cobra venom (*Naja naja naja*). *Methods Enzymol* **71**: 703–710, 1981.
 26. Pruzanski W, Bogoch E, Stefanski E, Wloch M and Vadas P, Enzymatic activity and distribution of phospholipase A₂ in human cartilage. *Life Sci* **48**: 2457–2462, 1991.
 27. Berg OG, Yu B-Z, Rogers J and Jain MK, Interfacial catalysis by phospholipase A₂: Determination of the interfacial kinetic rate constants. *Biochemistry* **30**: 7283–7297, 1991.
 28. Jain MK and Gelb MH, Phospholipase A₂-catalyzed hydrolysis of vesicles: Uses of interfacial catalysis in the scooting mode. *Methods Enzymol* **197**: 112–125, 1991.
 29. Jain MK, Yuan W and Gelb MH, Competitive inhibition of phospholipase A₂ in vesicles. *Biochemistry* **28**: 4135–4139, 1989.
 30. Yu L, Deems RA, Hajdu J and Dennis EA, The interaction of phospholipase A₂ with phospholipid analogues and inhibitors. *J Biol Chem* **265**: 2657–2664, 1990.
 31. Ehrlich GE, Concentration of tetracycline and minocycline in joint effusions following oral administration. *Pennsyl Med* **75**: 47–49, 1972.
 32. Breedveld FC, Dijkmans BAC and Mattie H, Minocycline treatment for rheumatoid arthritis: An open dose finding study. *J Rheumatol* **17**: 43–46, 1990.
 33. Pott H-G, Wittenborg A and Junge-Hülsing G, Long-term antibiotic treatment in reactive arthritis. *Lancet* **I**: 245–246, 1988.
 34. Panayi GS and Clark B, Minocycline in the treatment of patients with Reiter's syndrome. *Clin Exp Rheumatol* **7**: 100–101, 1989.
 35. Skinner M, Cathcart ES, Mills JA and Pinals RS, Tetracycline in the treatment of rheumatoid arthritis. *Arthritis Rheum* **14**: 727–732, 1971.
 36. Sugatani J, Saito K and Honjo I, *In vitro* actions of some antibiotics on phospholipases. *J Antibiot (Tokyo)* **32**: 734–739, 1979.
 37. Pruzanski W, Vadas P and Fornasier V, Inflammatory effect of intradermal administration of soluble phospholipase A₂ in rabbits. *J Invest Dermatol* **87**: 380–383, 1986.
 38. Edelson JD, Vadas P, Villar J, Mullen JBM and Pruzanski W, Acute lung injury induced by phospholipase A₂. Structural and functional changes. *Am Rev Respir Dis* **143**: 1102–1109, 1991.
 39. Jain MK, Rogers J, Johagirdar DV, Marecek JF and Ramirez F, Kinetics of interfacial catalysis of phospholipase A₂ in intravesicular scooting mode and heterofusion of anionic and zwitterionic vesicles. *Biochim Biophys Acta* **860**: 435–447, 1986.
 40. Flower RJ, Wood JN and Parente L, Macroscortin and the mechanism of action of the glucocorticoids. *Adv Inflammation Res* **7**: 61–70, 1984.
 41. Jain MK and Berg OG, The kinetics of interfacial catalysis by phospholipase A₂ and regulation of interfacial activation: Hopping versus scooting. *Biochim Biophys Acta* **1002**: 127–156, 1989.
 42. Goldhammer AR, Jain MK and Cordes EH, Phospholipases. III. Effects of ionic surfactants on the

- phospholipase-catalyzed hydrolysis of unsonicated egg lecithin liposomes. *J Membr Biol* 23: 293–304, 1975.
43. Vishwanath BS, Kini RM and Gowda TV, Characterization of three edema-inducing phospholipase A₂ enzymes from habu (*Trimeresurus flavoviridis*) venom and their interaction with the alkaloid aristolochic acid. *Toxicon* 25: 501–515, 1987.
44. Nevalainen TJ, The role of phospholipase A in acute pancreatitis. *Scand J Gastroenterol* 15: 641–650, 1980.
45. Nishijima J, Okamoto M, Ogawa M, Kosaki G and Yamamano T, Purification and characterization of human pancreatic phospholipase A₂ and development of a radioimmunoassay. *J Biochem (Tokyo)* 94: 137–147, 1983.
46. Geokas MC (Moderator), Acute pancreatitis. *Ann Intern Med* 103: 86–100, 1985.